Know who helps after the medicine arrives.

Get the next conversation into the plan.

Ask how the clinician checks progress, how you report problems, and how decisions to change the plan are made.

Ask what the service can handle by messages and what needs a live or local visit.

The national group of state medical boards recommends a visit in person when you need an examination or another local test.

If you move or travel, ask how that affects the next visit.

As of September 26, 2026, the clinician’s permission to treat you had to cover the state you were in when the visit took place.

Ask about delivery and the label.

Ask the pharmacy to explain storage, the expiry information, and what to do if the parcel arrives damaged.

FDA consumer guidance flags damaged packaging and missing instructions as reasons for concern.

For medicines in tirzepatide’s group, the FDA advises against using an injection that arrives warm or without needed refrigeration.

Ask the pharmacy for an answer about an uncertain delivery before using the product.

A label or device question is a question for the pharmacy or prescriber.

Keep an easy record.

• The exact medicine and pharmacy names.
• The date symptoms started and what changed.
• Questions that came up between visits.
• The next agreed check and how to reach the care team.

The FDA accepts reports of medicine problems from patients through MedWatch.

MedWatch is its medicine-problem reporting programme.

A report by itself cannot establish that the problem was caused by the medicine.

Reporting and getting care are separate tasks; the reading page links to the reporting service.